{
    "organizations": [],
    "uuid": "34faddc0c92c97c9cb6130cfdbe9d68a26f0ad3a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-eli-lilly-announces-positive-top-l/brief-eli-lilly-announces-positive-top-line-phase-3-results-for-taltz-idUSFWN1Q30Y0",
    "ord_in_thread": 0,
    "title": "Eli Lilly Announces Positive Top-Line Phase 3 Results For Taltz",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - Eli Lilly And Co:\n* LILLY ANNOUNCES POSITIVE TOP-LINE PHASE 3 RESULTS FOR TALTZ® (IXEKIZUMAB) IN ANKYLOSING SPONDYLITIS (RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS)\n* ELI LILLY AND CO - TALTZ(®) (IXEKIZUMAB) MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN COAST-V\n* ELI LILLY AND CO - PLANS TO SUBMIT DETAILED DATA FROM COAST-V FOR DISCLOSURE AT SCIENTIFIC MEETINGS AND IN PEER-REVIEWED JOURNALS LATER THIS YEAR\n* ELI LILLY AND CO - PLANS TO SUBMIT FOR REGULATORY APPROVALS PENDING ADDITIONAL DATA FROM ONGOING TALTZ DEVELOPMENT PROGRAM LATER THIS YEAR\n* ELI LILLY AND CO - ‍TALTZ DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT IN SIGNS AND SYMPTOMS OF AS, WHEN COMPARED TO PLACEBO​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-13T20:04:00.000+02:00",
    "crawled": "2018-02-14T12:44:34.026+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "eli",
        "lilly",
        "co",
        "lilly",
        "announces",
        "positive",
        "phase",
        "result",
        "ixekizumab",
        "ankylosing",
        "spondylitis",
        "radiographic",
        "axial",
        "spondyloarthritis",
        "eli",
        "lilly",
        "co",
        "taltz",
        "ixekizumab",
        "met",
        "primary",
        "key",
        "secondary",
        "endpoint",
        "eli",
        "lilly",
        "co",
        "plan",
        "submit",
        "detailed",
        "data",
        "disclosure",
        "scientific",
        "meeting",
        "journal",
        "later",
        "year",
        "eli",
        "lilly",
        "co",
        "plan",
        "submit",
        "regulatory",
        "approval",
        "pending",
        "additional",
        "data",
        "ongoing",
        "taltz",
        "development",
        "program",
        "later",
        "year",
        "eli",
        "lilly",
        "co",
        "demonstrated",
        "statistically",
        "significant",
        "improvement",
        "sign",
        "symptom",
        "compared",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}